Immutep (IMM.AX) drops to A$0.061 16 Mar 2026: heavy volume signals reprice

The IMM.AX stock closed at A$0.061 on 16 Mar 2026 after Immutep Limited confirmed a halt to a late-stage lung cancer trial. Trading was extremely active with 228,374,534 shares changing hands, far above the 10,168,881 average. The market closed with the ASX-listed biotechnology company sharply repriced, reflecting trial risk and fresh analyst downgrades. We look at financials, technicals, Meyka AI grading, and what the heavy volume means for short-term liquidity and longer-term value.